

Ingrid A Mayer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1507893/publications.pdf>

Version: 2024-02-01

79
papers

8,481
citations

117625

34
h-index

74163

75
g-index

81
all docs

81
docs citations

81
times ranked

12472
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment Exposure and Discontinuation in the PALbociclib CoLLaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 449-458.	1.6	25
2	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 282-293.	1.6	88
3	Abstract P4-10-02: Patient-reported outcomes in EA1131: A randomized phase III trial of platinum vs. capecitabine in patients with residual triple-negative breast cancer after neoadjuvant chemotherapy. <i>Cancer Research</i> , 2022, 82, P4-10-02-P4-10-02.	0.9	1
4	Abstract P3-14-11: Mammaprint and Blueprint identify genomic differences in HR+ HER2- breast cancers from young Black and White women. <i>Cancer Research</i> , 2022, 82, P3-14-11-P3-14-11.	0.9	0
5	Abstract PD13-01: Balixafortide (a CXCR4 antagonist)+eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer: An international, randomized, phase 3 trial (FORTRESS). <i>Cancer Research</i> , 2022, 82, PD13-01-PD13-01.	0.9	1
6	Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 127-139.	2.5	15
7	Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer. <i>Cancer Research Communications</i> , 2022, 2, 286-292.	1.7	2
8	Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1963.	7.4	81
9	Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial. <i>Clinical Infectious Diseases</i> , 2021, 72, e835-e843.	5.8	103
10	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. <i>Clinical Breast Cancer</i> , 2021, 21, 80-91.e7.	2.4	140
11	Racial/Ethnic Disparities in All-Cause Mortality among Patients Diagnosed with Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2021, 81, 1163-1170.	0.9	10
12	At the Bedside: Profiling and treating patients with CXCR4-expressing cancers. <i>Journal of Leukocyte Biology</i> , 2021, 109, 953-967.	3.3	15
13	Radiotherapy after breast-conserving surgery for elderly patients with early-stage breast cancer: A national registry-based study. <i>International Journal of Cancer</i> , 2021, 148, 857-867.	5.1	2
14	Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3896-3904.	7.0	36
15	Abstract PD11-05: Diabetes decreases overall survival in women with breast cancer in the southern community cohort study. , 2021, , .		1
16	Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5207.	4.1	20
17	Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial. <i>Npj Breast Cancer</i> , 2021, 7, 74.	5.2	16
18	Patient-Reported Outcomes in Patients With PI3KCA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1. <i>Journal of Clinical Oncology</i> , 2021, 39, 2005-2015.	1.6	23

#	ARTICLE	IF	CITATIONS
19	Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases. <i>Frontiers in Genetics</i> , 2021, 12, 707836.	2.3	9
20	Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab066.	2.9	5
21	Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. <i>Journal of Clinical Oncology</i> , 2021, 39, 2539-2551.	1.6	78
22	Reply to T. Shimoi et al and Y. Shimanuki et al. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01905.	1.6	3
23	New targets in endocrine-resistant hormone receptor-positive breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19, 511-521.	0.3	1
24	Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 101-109.	7.0	14
25	Systemic Inflammation After Radiation Predicts Locoregional Recurrence, Progression, and Mortality in Stage II-III Triple-Negative Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 268-276.	0.8	16
26	Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 357-364.	2.5	5
27	Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer. <i>Drugs</i> , 2020, 80, 1685-1697.	10.9	72
28	Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5668-5681.	7.0	37
29	Disparities in BRCA counseling across providers in a diverse population of young breast cancer survivors. <i>Genetics in Medicine</i> , 2020, 22, 1088-1093.	2.4	10
30	Combining Adjuvant Radiotherapy With Capecitabine in Chemotherapy-resistant Breast Cancer: Feasibility, Safety, and Toxicity. <i>Clinical Breast Cancer</i> , 2020, 20, 344-352.e1.	2.4	11
31	Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3947-3957.	7.0	54
32	Reciprocal expression of Annexin A6 and RasGRF2 discriminates rapidly growing from invasive triple negative breast cancer subsets. <i>PLoS ONE</i> , 2020, 15, e0231711.	2.5	11
33	Overall Mortality After Diagnosis of Breast Cancer in Men vs Women. <i>JAMA Oncology</i> , 2019, 5, 1589.	7.1	103
34	PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 31.	5.2	31
35	Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2395-2405.	27.0	349
36	Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 1929-1940.	27.0	1,582

#	ARTICLE	IF	CITATIONS
37	Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. <i>Nature Communications</i> , 2019, 10, 1373.	12.8	252
38	Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 741-751.	27.0	542
39	Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. <i>Clinical Cancer Research</i> , 2019, 25, 7381-7387.	7.0	13
40	Alpelisib Plus Fulvestrant in <i>PIK3CA</i> -Altered and <i>PIK3CA</i> -Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, e184475.	7.1	187
41	<i>PIK3CA</i> C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K Inhibitors. <i>Clinical Cancer Research</i> , 2018, 24, 1426-1435.	7.0	27
42	Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program. <i>Targeted Oncology</i> , 2018, 13, 61-68.	3.6	8
43	Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). <i>Journal of Clinical Oncology</i> , 2018, 36, 2621-2629.	1.6	52
44	Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3126-3133.	1.6	52
45	A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 109.	5.0	48
46	Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 111-121.	27.0	1,558
47	Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 371-378.	2.5	9
48	A 3q gene signature associated with triple negative breast cancer organ specific metastasis and response to neoadjuvant chemotherapy. <i>Scientific Reports</i> , 2017, 7, 45828.	3.3	21
49	PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses. <i>Clinical Cancer Research</i> , 2017, 23, 3371-3384.	7.0	80
50	18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. <i>Clinical Cancer Research</i> , 2017, 23, 3053-3060.	7.0	66
51	Association of FGFR1 with ER± Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6138-6150.	7.0	94
52	Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	91
53	A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2017, 1, 83-88.	0.4	4
54	Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2141-2148.	1.6	283

#	ARTICLE	IF	CITATIONS
55	The PI3K/AKT Pathway as a Target for Cancer Treatment. Annual Review of Medicine, 2016, 67, 11-28.	12.2	631
56	Breast Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1475-1485.	4.9	134
57	Advanced Hormone-Sensitive Breast Cancer: Overcoming Resistance. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 655-657.	4.9	2
58	Effect of Metformin vs Placebo on and Metabolic Factors in NCIC CTG MA.32. Journal of the National Cancer Institute, 2015, 107, djv006-djv006.	6.3	112
59	Clinical Implications of Mutations in the PI3K Pathway in HER2+ Breast Cancer: Prognostic or Predictive?. Current Breast Cancer Reports, 2015, 7, 210-214.	1.0	5
60	Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2015, 33, 2695-2704.	1.6	279
61	Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). Journal of Clinical Oncology, 2015, 33, 2623-2631.	1.6	49
62	Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer. Cancer Research, 2015, 75, 405-414.	0.9	53
63	PIK3CA Activating Mutations: A Discordant Role in Early Versus Advanced Hormone-Dependent Estrogen Receptor-Positive Breast Cancer?. Journal of Clinical Oncology, 2014, 32, 2932-2934.	1.6	32
64	Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel. Oncologist, 2014, 19, 616-622.	3.7	94
65	New Strategies for Triple-Negative Breast Cancer—Deciphering the Heterogeneity. Clinical Cancer Research, 2014, 20, 782-790.	7.0	242
66	Molecular Heterogeneity of Triple-Negative Breast Cancer. Current Breast Cancer Reports, 2014, 6, 154-158.	1.0	58
67	Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. Journal of Clinical Oncology, 2014, 32, 1202-1209.	1.6	159
68	Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103. Journal of Clinical Oncology, 2014, 32, 500-500.	1.6	38
69	SU2C phase Ib study of the PI3K± inhibitor BYL719 with letrozole in ER+/HER2± metastatic breast cancer (MBC). Journal of Clinical Oncology, 2014, 32, 516-516.	1.6	2
70	Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003. Journal of Clinical Oncology, 2014, 32, 536-536.	1.6	5
71	Prediction and early detection of anthracycline-related cardiotoxicity using cardiac biomarkers. Journal of Clinical Oncology, 2014, 32, 9644-9644.	1.6	5
72	Phase II, randomized, placebo-controlled study of BYL719 or buparlisib (BKM120) with letrozole for neoadjuvant treatment of postmenopausal women with HR+/HER2±, PIK3CA mutant or wild-type, breast cancer (BC). Journal of Clinical Oncology, 2014, 32, TPS655-TPS655.	1.6	1

#	ARTICLE	IF	CITATIONS
73	Prevention of stomatitis in patients with hormone receptor- positive advanced breast cancer treated with everolimus plus exemestane: A phase II study of a steroid-based mouthwash.. Journal of Clinical Oncology, 2014, 32, TPS661-TPS661.	1.6	1
74	Vitamin B12 (Vit B12) biochemical (BCH) deficiency (DEF) in non-diabetic breast cancer (BC) patients on NCIC CTG MA.32: A phase III randomized adjuvant BC trial comparing metformin (Met) to placebo (Pl).. Journal of Clinical Oncology, 2014, 32, 542-542.	1.6	1
75	TBCRC028: A phase Ib/II trial of GDC-0941 (a PI3K inhibitor) in combination with cisplatin in metastatic androgen receptor-negative triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2014, 32, TPS1148-TPS1148.	1.6	1
76	Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC).. Journal of Clinical Oncology, 2013, 31, 1033-1033.	1.6	3
77	Subtyping of triple-negative breast cancer. Clinical Advances in Hematology and Oncology, 2013, 11, 731-2.	0.3	2
78	Discordant Cellular Response to Presurgical Letrozole in Bilateral Synchronous ER+ Breast Cancers with a <i>KRAS</i> Mutation or <i>FGFR1</i> Gene Amplification. Molecular Cancer Therapeutics, 2012, 11, 2301-2305.	4.1	22
79	Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Research and Treatment, 2011, 126, 215-220.	2.5	170